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Introduction
Ebola virus (EBOV) is one of the most deadly viral infections of 
humans, with mortality rates being reported between 50%–70%. 
The recent EBOV disease (EVD) epidemic in Western Africa pre-
sented huge challenges for public health and for conducting basic 
science and translational clinical research (1, 2). As of September 
13, 2015, WHO estimated that there were 28,265 cases of EVD, with 
11,308 deaths associated with the recent West African outbreak (3).
Clinical observations show that patients with EVD who did not 
survive showed severe symptoms and clinical signs during the early 
phase of the disease; many progressed to developing multiorgan 
failure, resulting in death by the end of the second week. Patients 
who survived typically began to improve during the second week 
of illness. Performing clinical, laboratory, and pathogenesis studies 
during EVD outbreaks is extremely difficult due to biosafety, and 
logistical and operational issues. EBOV viral load in blood, or vire-
mia, may reflect the dynamic interaction between viral replication 
and clearance by the body’s immune system. While recent stud-
ies have suggested that EBOV viremia may be a predictor of clini-
cal outcome (4, 5), no accurate data are available on the temporal 
trends of kinetics of EBOV viremia during the course of the disease.
We conducted a study of the kinetics of EBOV viremia in 
patients with EVD who were managed in an Ebola Treatment 
Centre (ETC) in Goderich-Freetown, Sierra Leone. To obtain 
optimal information contained in datasets composed of sparse 
repeated measures, we used an inferential approach that has 
been recently applied to clinical infectious diseases (6) and 
microbial ecology (7).
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Bivariable and multivariable analyses to assess potential con­
founders. Bivariable analysis showed that EBOV viremia was 
significantly higher in nonsurvivors, patients who needed 
mechanical ventilation, and those who needed renal replace-
ment therapy (Table 1).
Multivariable analysis (Table 2) showed that only the clin-
ical outcome was independently associated with an increased 
level of viremia. Adjusted mean viremia at admission was 7.15 
logarithm (log) copies per ml (cp/ml) (95% CI, 6.76–7.54) and 
8.33 log cp/ml (95% CI, 7.97–8.68) in survivors and nonsurvi-
vors, respectively (P < 0.001). The mean of the highest viremia 
values recorded during hospitalization was 7.40 log cp/ml (95% 
CI, 7.01–7.77) and 8.67 log cp/ml (95% CI, 8.32–9.02) in survi-
vors and nonsurvivors, respectively (P < 0.001).
Results
Descriptive analysis. Between December 13 ,2014, and April 20, 
2015, a total of 101 patients with laboratory-confirmed diagnosis 
of EVD were admitted to the EMERGENCY NGO ETC in Goder-
ich-Freetown, Sierra Leone. Of 101 patients, there were 50 survi-
vors and 51 nonsurvivors (50.5% mortality). Selection of patients 
for this is depicted in Figure 1. Table 1 shows the age groups, sex, 
and clinical characteristics of 84 patients (38 survivors and 46 
nonsurvivors) that were studied for analysis. The mean time 
between onset of symptoms and admission was 4.53 days (SD 
2.48). In patients who did not survive, the mean time between 
onset of symptoms and death was 9.04 days (SD 3.17). The mean 
time between onset of symptoms and first undetectable EBOV 
viremia in survivors was 12.71 days (SD 3.84).
Table 1. Bivariable analysis of the patients included in the analysis
Subjects EBOV viremia at admission (log cp/ml) Highest EBOV viremia during hospital stay (log cp/ml)
Feature No. Mean (95% CI) DifferenceA (95% CI) PB Mean (95% CI) DifferenceA (95% CI) PB
Sex Female 44 7.72 (7.34–8.10) Base 0.567 7.92 (7.52 to 8.32) Base 0.206
Male 40 7.88 (7.48–8.28) +0.16 (–0.39 to +0.71) 8.29 (7.86–8.70) +0.37 (–0.21 to +0.94)
Age 0–19 20 8.17 (7.61–8.73) Base 0.326 8.44 (7.85–9.03) Base
20–39 42 7.67 (7.28–8.06) –0.50 (–1.18 to +0.19) 7.99 (7.58–8.40) –0.45 (–1.17 to +0.27) 0.414
≥40 22 7.69 (7.16–8.23) –0.48 (–1.25 to +0.30) 7.97 (7.40–8.53) –0.47 (+1.29 to –0.35)
Malaria Neg. 74 7.74 (7.45–8.03) Base 0.295 8.02 (7.71–8.32) Base 0.173
Pos. 10 8.19 (7.40–8.99) +0.45 (–0.40 to +1.30) 8.63 (7.80–9.46) +0.61 (–0.27 to +1.50)
DrugsC None 60 7.89 (7.56–8.21) Base 0.450 8.05 (7.71–8.39) Base 0.446
AmiodaroneD 19 7.47 (6.89–8.05) –0.42 (–1.08 to +0.24) 8.03 (7.41–8.63) –0.03 (–0.72 to +0.67)
MAbsE 5 7.93 (6.77–9.03) +0.14 (–1.16 to +1.19) 8.82 (7.64–10.01) +0.77 (–0.45 to +2.01)
AdmissionF <5 days 42 7.74 (7.35–8.13) Base 0.695 8.15 (7.74–8.56) Base 0.686
≥5 days 42 7.85 (7.46–8.24) +0.11 (–0.44 to +0.66) 8.03 (7.62–8.44) –0.12 (–0.70 to +0.45)
Outcome Survivors 38 7.11 (6.75–7.46) Base <0.001 7.28 (6.92–7.64) Base <0.001
Nonsurvivors 46 8.36 (8.03–8.68) +1.25 (+0.76 to +1.73) 8.75 (8.43–9.08) +1.47 (+0.99 to 1.96)
Mechanical ventilation No 56 7.54 (7.22–7.86) Base 7.73 (7.40–8.06) Base
≥1 day 28 8.31 (7.85–8.77) +0.77 (+0.21 to +1.33) <0.001 8.81 (8.34–9.28) +1.08 (+0.51 to +1.65) <0.001
Renal replacement No 66 7.66 (7.35–9.97) Base 7.89 (7.58–8.20) Base
≥1 day 18 8.25 (7.70–8.87) +0.62 (–0.04 to + 1.28) 0.063 8.82 (8.22–9.42) +0.93 (+0.25 to +1.60) 0.008
Overall 84 7.80 (7.52–8.07) – – 8.09 (7.80–8.38) – –
HIV Ab, test for anti-HIV antibodies; MAbs, anti-EBOV monoclonal antibodies. ADifference of mean EBOV viremia in log cp/ml in comparison to base level; 
BP value according to standard linear regression model (F test); Cdrug with potential effect on EBOV viremia; Damiodarone was administered at admission 
(day 0) as 5 mg/kg in 1 hour i.v. Between days 1–3, patient received amiodarone i.v. 20 mg/kg/24 hours (continuous infusion); between days 4–10, patients 
received amiodarone per os 10 mg/kg every 8 hours. EOne patient received ZMAb; 1 patient received ZMAb in addition to amiodarone; 2 patients received 
ZMAPP; 1 patient received ZMAPP in addition to amiodarone. FTime between symptom onset and hospital admission.
Figure 1. Selection of patients. Between December 13, 2014, and April 
20, 2015, 101 patients tested positive to EBOV RT-PCR, of whom 84 were 
included in the analysis. For these 84 patients, a total of 295 measurable 
EBOV viremia results were available and 76 had undetectable EBOV RNA.
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cantly higher in nonsurvivors compared with survivors (0.94 log 
cp/ml [95% CI, 0.21–1.67]; P = 0.011). This difference increased to 
1.50 log cp/ml (95% CI, 0.99–2.01; P < 0.001) and 4.94 log cp/ml 
(95% CI, 3.63–6.25; P < 0.001) at day 7 and day 13 after the onset 
of symptoms, respectively (Table 4).
Survivors reached their viremic peak value earlier than non-
survivors (day 5 versus day 7 after symptom onset, respectively). 
The mean peak value of viremia in survivors was lower than in 
Multivariable analyses showed no significant association 
between EBOV viremia at admission and the need for mechan-
ical ventilation (P = 0.649) or the need for renal replacement 
(P = 1.00). Similarly, there was no significant association between 
the mean of the highest viremia values during hospitalization and 
the need for mechanical ventilation (P = 0.316) or the need for 
renal replacement (P = 0.745).
Modeling the kinetics of EBOV viremia. Temporal trends of 
EBOV viremia levels for the 84 patients 
were modeled using 275 quantitative 
PCR (qPCR) results (3.3 determinations 
per patient) between days 2 and 13 after 
first symptom onset. This range was 
selected in order to have at least 10 real 
observations for each time point esti-
mate, and it led to the exclusion of 20 
EBOV viremia determinations between 
days 14 and 17. The final model included 
the random intercept at patient level, 
the random slope at time level, EBOV 
viremia as a dependent variable and 
2 independent variables (i.e., time 
after symptom onset, as a continuous 
quadratic term), and patient’s clinical 
outcome (as a binary term). According 
to model-based likelihood ratio tests 
(LRT), we also included full interac-
tion (i.e., linear and quadratic) between 
the 2 independent variables. Following 
the results of multivariable analysis 
(Table 2), no potential confounder was 
included. Model details and parame-
ters for fixed and random coefficients 
are shown in Table 3.
Variation of EBOV viremia over time 
since symptom onset. Between days 2 
and 13 after the onset of symptoms, 
EBOV viremia in nonsurvivors was 
always significantly higher than in sur-
vivors (Table 4). At day 2 after onset of 
symptoms (which represents the model 
intercept), viremia levels were signifi-
Table 2. Multivariable analysis of the patients included in the analysis
Subjects EBOV viremia at admission (log cp/ml) Highest EBOV viremia during hospital stay (log cp/ml)
Feature No. Adjusted mean  
(95% CI)
Adjusted difference 
(95% CI)
PA Adjusted mean  
(95% CI)
Adjusted difference  
(95% CI)
PA
Outcome Survivors 38 7.15 (6.76–7.54) Base <0.001 7.40 (7.01–7.77) Base <0.001
Nonsurvivors 46 8.33 (7.97–8.68) +1.17 (+0.61 to +1.73) 8.67 (8.32–9.02) 1.27 (+0.71 to 1.83)
Mechanical ventilation No 56 7.74 (7.40–8.08) Base 7.97 (7.63–8.31) Base
≥1 day 28 7.90 (7.38–8.43) +0.16 (–0.54 to +0.86) 0.649 8.33 (7.80–8.85) +0.35 (–0.34 to +1.05) 0.316
Renal replacement No 66 7.80 (7.50–8.08) Base 8.01 (7.77–8.36) Base
≥1 day 18 7.80 (7.15–8.44) –0.00 (–0.75 to +0.75) 1.00 8.19 (7.55–8.83) +0.12 (–0.62 to +0.87) 0.745
Log cp/ml, decimal log of EBOV RNA copies per milliliter. AValue according to standard multivariable linear regression model (F test).
Table 3. Full model parameters
Overall model parameters
 Number of observation: RNA determination 275
 Random intercept group variable: patients 84
 Random slope variable (time): days 2–13
 Observation per patients: (RT-PCR with detectable RNA levels) 3.3
Model selection
 Random effect (assessed on null model)
  Random intercept vs. standard linear regression model P < 0.001
  Random slope vs. random intercept model P < 0.001
 Functional form of association between time and viremia
  Linear vs. quadratic P < 0.001
  Quadratic vs. cubic P = 0.699
  Quadratic vs. 4th power P = 0.911
  Quadratic vs. 6th power P = 0.543
  Quadratic vs. categorical 12-level P = 0.560
  Interaction between time and outcome vs. no interaction P < 0.001
Fixed effect parameters Coeff. 95% CI P
 Time after symptom onset: linear 0.34 0.14 to 0.54 0.001
 Time after symptom onset: quadratic –0.07 –0.08 to –0.05 <0.001
 Clinical outcome: binary (0 survived, 1 died) 0.94 0.21 to 1.67 0.011
 Interaction
  Time after symptom onset (linear) and clinical outcome –0.10 –0.36 to 0.16 0.463
  Time after symptom onset (quadratic) and clinical outcome 0.04 0.02 to 0.06 <0.001
  Constant: Intercept at Time after symptom onset = 2 7.03 6.49 to 7.58 <0.001
Random effect parameters Coeff. 95% CI
 Random slope 0.05 0.03 to 0.08
 Random intercept 0.61 0.30 to 1.23
 Unstructured covariance –0.08 –0.17 to –0.01
 Residual variance 0.26 0.21 to 0.33
Coeff., coefficient.
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The overall results of the model are shown in 
Table 4 and Figure 2.
Discussion
To our knowledge, this is the first study that has 
modeled the kinetics of EBOV viremia in patients 
with EVD. It is also the first to highlight the sig-
nificant link between the temporal trend of EBOV 
viremia and its relationship to clinical outcome. 
There are several notable findings of our study. 
Firstly, early in the course of EVD, soon after the 
onset of symptoms, EBOV viral load levels were 
significantly higher in those patients who died 
compared with those who survived. Secondly, 
EVD patients who survived reached their peak 
viral-load levels earlier than nonsurvivors. The 
mean time between onset of symptoms and first 
undetectable EBOV viremia in survivors was 
12.71 days (SD 3.84) compared with 9.04 days (SD 
3.17) between symptom onset and death in non-
survivors. Thirdly, EBOV viremia between days 
2 and 13 after onset of symptoms was a quadratic 
function of the time. While EBOV viral load lev-
els similarly increased in both survivors and non-
survivors, after peak values were reached, viral 
decay in survivors was much more pronounced 
than in nonsurvivors. There are several possi-
ble reasons for this observation, such as differ-
ences in host genetic factors, innate and adaptive 
immune responses, and underlying risk factors 
and co-morbidities (8–10). Further studies will be 
required in any future outbreak to determine the 
potential contributions of each of these factors.
Our findings confirm the inference from clini-
cal studies in West Africa (4, 5) and past EVD out-
breaks (8, 9, 11–13) of the possible link between 
early EBOV viremia and a fatal outcome in EVD patients. The 
case fatality rate in Sierra Leone ranged between 33% and 94% in 
EVD patients presenting with an EBOV viremia less than 5 log cp/
ml and more than 7 log cp/ml, respectively (5). Our findings also 
concur with those of Towner and colleagues who studied EVD 
patients from the outbreak in Sudan. They indicated that peak 
viremia in survivors was observed about 2 days earlier than in non-
survivors. In addition, despite the potential differences in EBOV 
strains and the RT-PCR assays, the observed mean values of peak 
viremia for either survivors or nonsurvivors were comparable to 
that estimated in our study (12).
Our data is relevant to EVD patients in the West Africa setting. 
Despite the best available level of supportive care provided in the 
EMERGENCY ETC in Goderich-Freetown, Sierra Leone, the mor-
tality rate was high, at >40%. This was twice as high when com-
pared with the mortality rate for the 26 EVD patients who received 
healthcare in Europe (14, 15) and North America (14, 16), of whom 
5 died (20% mortality) (17). While the majority of patients with 
the lowest EBOV viremia levels cleared the virus within the time 
frame estimated by our model (18), several patients had presented 
with very high EBOV viremia levels on admission but still went on 
nonsurvivors (7.46 log cp/ml; 95% CI, 7.17–7.76 vs. 8.60 log cp/
ml; 95% CI, 8.27–8.93). Model estimates for the peak values were 
largely consistent with the observed mean of the highest viremia 
levels recorded during hospitalization (7.28 and 8.75 log cp/ml 
EBOV RNA in survivors and nonsurvivors, respectively; Table 1). 
Among survivors, EBOV viremia reached the limit of detection 
(LOD) between day 12 and 13 (Figure 2), coinciding with observed 
mean time between symptom onset and first undetectable EBOV 
viremia (i.e., 12.71 days).
In both survivors and nonsurvivors, EBOV viral load 
increased in the early phase of EVD and started decreasing from 
day 5 in survivors and from day 7 in nonsurvivors. According to 
the quadratic function (i.e., inverted u-shaped curve), by day 2 
after symptom onset, the increase of EBOV viremia before peak 
values was similar in survivors and nonsurvivors, as modeled 
by the nonsignificant interaction between linear coefficient for 
time and clinical outcome (Table 3). In contrast, after peak val-
ues, the reduction of viremia was significantly more pronounced 
in survivors than in nonsurvivors, as modeled by the significant 
positive interaction between the negative quadratic coefficient 
for time and clinical outcome (Table 3).
Table 4. Predicted value of EBOV viremia in survivors and nonsurvivors
DaysA Patients EBOV viremia DifferenceC
Outcome No.B log cp/ml (95%CI) log cp/ml (95%CI) PD
2 Survivors 5 7.03 (6.49–7.58) Base 0.011
Nonsurvivors 9 7.97 (7.49–8.45) 0.94 (+0.21 to 1.67)
3 Survivors 5 7.31 (6.90–7.71) Base 0.001
Nonsurvivors 7 8.19 (7.83–8.55) 0.88 (0.34–1.42)
4 Survivors 6 7.45 (7.13–7.77) Base <0.001
Nonsurvivors 14 8.36 (8.08–8.65) 0.91 (0.48–1.34)
5 Survivors 11 7.46 (7.17–7.76) Base <0.001
Nonsurvivors 17 8.49 (8.22–8.75) 1.02 (0.62–1.42)
6 Survivors 15 7.35 (7.02–7.68) Base <0.001
Nonsurvivors 20 8.57 (8.28–8.85) 1.22 (0.78–1.66)
7 Survivors 13 7.10 (6.71–7.49) Base <0.001
Nonsurvivors 16 8.60 (8.27–8.93) 1.50 (0.99–2.01)
8 Survivors 13 6.72 (6.27–7.18) Base <0.001
Nonsurvivors 21 8.59 (8.21–8.96) 1.86 (1.27–2.45)
9 Survivors 12 6.22 (5.69–6.75) Base <0.001
Nonsurvivors 19 8.53 (8.08–8.97) 2.31 (1.62–3.00)
10 Survivors 12 5.58 (4.97–6.19) Base <0.001
Nonsurvivors 16 8.42 (7.90–8.94) 2.84 (2.04–3.64)
11 Survivors 6 4.81 (4.10–5.52) Base <0.001
Nonsurvivors 9 8.27 (7.65–8.88) 3.46 (2.52–4.39)
12 Survivors 8 3.91 (3.09–4.74) Base <0.001
Nonsurvivors 8 8.07 (7.33–8.81) 4.15 (3.05–5.26)
13 Survivors 8 2.89 (1.92–3.85) Base <0.001
Nonsurvivors 5 7.82 (6.94–8.71) 4.94 (3.63–6.25)
EBOV viremia values are predicted according to patients’ clinical outcomes. Analysis 
was carried out on 275 EBOV viremia determinations (114 from survivors and 161 from 
nonsurvivors). Log cp/ml, decimal log of EBOV RNA copies per milliliter. ADays after symptom 
onset; Bnumber of patients in the specific day after symptom onset (each patient can have 
only 1 EBOV RNA determination per day); Cdifference of mean EBOV viremia in log cp/ml 
between nonsurvivors and survivors; DP value according ANOVA-style joint tests.
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Methods
Study design, setting, and patient followup. We conducted a study of 
consecutive patients with laboratory-confirmed EVD who were admit-
ted for care in an Ebola treatment center (ETC) in Goderich-Free-
town (Sierra Leone), managed by the nongovernmental organization 
EMERGENCY (22). The ETC is endowed with an internal laboratory 
for molecular diagnosis of EVD, managed by Italian National Institute 
for Infectious Diseases “Lazzaro Spallanzani.”
Patients were followed up from the day of admission until the day 
of discharge.
Eligible patients and enrollment criteria. All patients with EVD 
who were admitted to ETC between December 13, 2014, and April 
20, 2015, were retrospectively enrolled in the study. Enrollment was 
restricted to those who had the time of onset of symptoms recorded 
and at least one quantifiable blood EBOV RNA result was available.
All EVD suspect cases (according to WHO definition; ref. 23) under-
went quantitative EBOV RT-PCR on plasma samples; those who tested pos-
itive received multiple EBOV RT-PCR tests during the hospital stay, as clini-
cally indicated. Confirmed EVD cases were discharged after 2 consecutive 
undetectable EBOV RNA RT-PCRs in blood taken at least 2 days apart. 
Patients were treated with supportive care according to a standardized pro-
tocol (including hemodynamic support, mechanical ventilation, and con-
tinuous renal replacement where necessary) developed by EMERGENCY 
NGO and approved by the Sierra Leone Ministry of Health. Some patients 
also received drugs with potential antiviral effect, on a case-by-case basis.
Variables. Viremia (as a continuous variable), reported as plasma 
concentration of EBOV RNA in the decimal log of cp/ml, was the 
dependent variable in all inferential models.
Patient’s clinical outcome (as a binary variable) and time since 
symptom onset (as a continuous variable) were used as the 2 a priori 
independent variables for the multilevel model. Eight additional vari-
ables were considered as potential confounders: age (as a categorical 
variable), sex (as a binary variable), HIV test result (as a binary vari-
able), malaria rapid test result (as a binary variable), receipt of drugs 
with any potential effect on EBOV viremia (as a categorical vari-
able), need for mechanical ventilation (as a binary variable), need for 
renal-replacement therapy (as a binary variable), and time between 
symptom onset and hospital admission (as a binary variable).
to survive (19, 20). This might be attributed to different levels of 
healthcare and the use of investigational antiviral treatments or 
differences in innate and acquired immune responses. It is also 
probable that these differences between the patients in our study 
and those who received therapy in Europe and North America are 
completely spurious because of the random error due to small 
numbers of observations.
Our study data was collected in real time during the ongo-
ing EVD outbreak in West Africa, and thus, our results should 
be viewed in light of several limitations. Firstly, as nonsurvi-
vors had EBOV RNA levels above 9 log cp/ml (i.e., beyond the 
estimated dynamic range of the test) more frequently than 
survivors, the model may have underestimated the difference 
between groups. Secondly, our study may have selection bias; 
we studied only patients who were admitted to hospital care 
and did not include patients at the end of both spectrums of 
EVD who did not seek or receive healthcare — those with ful-
minant disease or those with very mild illness. Thirdly, since 
multiple imputation techniques can be unreliable in multilevel 
models with random slope (21), we handled missing data with a 
list-wise deletion approach that might have introduced a selec-
tion bias. Fourthly, our study provides no statistically signifi-
cant evidence of association between a patient’s baseline con-
dition — such as age, sex, malaria coinfection, and use of drugs 
— with potential antiviral effect. We performed a sensitivity 
analysis (data not shown) and found that including patients 
who received amiodarone or monoclonal antibodies had no 
effect on the estimation of the coefficients of the multilevel 
model. Finally, given our study sample size and the real-time 
exploratory nature of our study, the model cannot be used to 
make predictions about EBOV viremia kinetics before day 2 
and after day 13 since symptom onset.
In conclusion, plasma concentrations of EBOV are signifi-
cantly different between survivors and nonsurvivors beginning 
very early after symptom onset and may indicate prognostic 
significance. Further studies focusing on the early phase of the 
disease are required to identify prognostic factors that deter-
mine patients’ outcomes.
Figure 2. EBOV kinetics. Linear predic-
tion of EBOV RNA blood levels (viremia) 
according to the time since symptom 
onset and patients’ clinical outcomes. All 
estimates were made on the full dataset, 
including 275 EBOV RNA determinations 
on the 84 patients. (A) Survivors: 38 
patients with 114 EBOV RNA determi-
nations. (B) Nonsurvivors: 46 patients 
with 161 EBOV RNA determinations. Dots 
indicate single EBOV RNA determina-
tion; black line indicates linear prediction 
according to linear multilevel model; green 
dashed line indicates the LOD of the EBOV 
RNA assay (3.11 log cp/ml).
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Information regarding day of hospital admission, day of death in 
nonsurvivors, day of first undetectable EBOV RT-PCR in survivors, 
and day of discharge was also collected.
Data collection and data quality assessment. Data of patients with 
EVD and EBOV RT-PCR results were recorded on a study-specific 
electronic database. Clinical data were manually collected and even-
tually crosschecked from clinical records by 2 independent investiga-
tors (M. Langer and G. Brogiato). The final assessment of data qual-
ity was carried out in a common session (conference call) between 
EMERGENCY NGO staff in Sierra Leone and INMI staff in Italy.
Laboratory methods. EBOV RNA testing was performed using a 
qPCR assay (RealStar Filovirus Screen RT-PCR 1.0 kit, Altona Diag-
nostics), with a LOD of 3.11 log cp/ml of EBOV RNA. Viral RNA quan-
tification was based on a standard reference curve provided by the kit 
producers, spanning up to 9 log cp/ml of EBOV RNA.
Malaria testing was performed by BinaxNOW Malaria rapid 
point-of-care test (Alere).
HIV testing was performed by Alere Determine HIV­1/2 Ag/Ab 
Combo rapid point-of-care test.
Statistics. Bivariable and multivariable standard linear regression 
models were used to confirm association between viremia and a patient’s 
clinical outcome, and to select potential confounders to be included in the 
multilevel regression model. Exposures with fewer than 5 observations 
were excluded. All covariates with P ≤ 0.100 in bivariable analyses were 
included in multivariable analysis. All variables with P ≤ 0.100 in the mul-
tivariable analysis were included in the final multilevel model.
Variation of EBOV viremia over time after symptom onset was mod-
eled according to a polynomial maximum likelihood multilevel linear 
regression model with random intercept at patient level and random 
slope at time level (24). These models, historically referred as growth-
curve models (25) and eventually referred to latent trajectory models (26), 
represent a prominent group of mixed-effect linear regression techniques 
frequently used to analyze repeated measures data taken over time (e.g., 
clustered longitudinal data). In fact, the flexibility of these models makes 
it possible to describe linear and nonlinear (polynomial) variation of a 
continuous dependent variable (in this study, EBOV viremia) over time 
(in this study, the time after symptom onset). As our study is, in principle, 
an exploratory research, we preferred the polynomial approach over other 
relevant inferential techniques, such multilevel spline regression model 
(27). In fact, we lacked any solid background knowledge about EBOV 
kinetics in order to define the number and the temporal position of the 
knots to implement a spline model.
Random intercept and random slope were assessed by LRT. In 
particular, the random intercept was included if LRT P value for a stan-
dard null model (i.e., the model including only the dependent variable) 
versus the random intercept null model was less than 0.100; random 
slope was included if LRT P value for the random intercept null model 
versus the random intercept plus the random slope null model was less 
than 0.100. The model was implemented with no assumption about 
variance-covariance structure (unstructured matrix structure for het-
eroskedastic random effects models).
The functional form of association between EBOV viremia and 
time after symptom onset (from days 2–13) was decided by LRT to 
assess subsequent polynomial models with viremia (dependent vari-
able) and time (independent variable) as a continuous variable with 
increasing exponential power, or as a 12-level categorical variable. In 
this way, the best functional form for time after symptom onset was 
chosen according to simplicity and fitness criteria by preferring the 
most complex model (i.e., that including highest polynomial power) 
over the simplest one whenever LRT P ≤ 0.100.
Interaction between patient’s outcome (either survivor or nonsur-
vivor) and time since symptom onset was assessed by LRT. Interaction 
terms were included for LRT P value ≤ 0.100.
Model-based punctual estimates of EBOV viremia at different 
times, difference between survivors and nonsurvivors with relative 
95% CI, and P values were obtained by linear prediction and ANOVA-
style joint tests.
All analyses were carried out by STATA 13.1 statistical package.
Study approval. This work was conducted as part of the inter-
national public health response to help the containment of the out-
break in Sierra Leone and, therefore, informed consent was not 
obtained from individual patients. Ethics approval was obtained from 
the INMI Lazzaro Spallanzani Ethic Board (protocol registration 307) 
to use, analyze, and publish unidentified, anonymous data collected 
during clinical management of patients.
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